MindMed is Preparing for a Presentation at the Benzinga Global Small Cap Conference
MindMed’s (MNMD) brass is preparing to provide a much-anticipated update pertaining to its progress in the development of psychedelics for mental health at the upcoming Benzinga Global Small Cap Conference. MindMed, a pioneer in the biotech space, is hard at work creating psychedelics to improve the human condition, particularly among those saddled by depression, anxiety and PTSD.
About the Upcoming Conference
Robert Barrow, the Chief Executive Officer of MindMed, is set to provide an update on the company’s therapeutic psychedelics. Barrow will also conduct one-on-one meetings with investors at the conference. The Benzinga Global Small Cap conference is scheduled for December 8th and 9th. The conference will be virtual this year, meaning investors and others can tune in through their web-connected computing devices. MindMed’s corporate update and investor meetings are set to kick off on Thursday, December 9 at 4 PM Eastern.
Those interested in tuning into the conference webcast can do so by clicking here. The webcast will be recorded so those who are unable to tune in live will be able to catch up by accessing the content through the company’s web archives. If you will be working or otherwise busy when the MindMed conference takes place this upcoming Thursday, surf the web on over to the company’s website for a recording of the content.
You can access the recorded webcast to learn more about MindMed’s progress in the context of developing psychedelic therapies by checking out the “Investors” section the biotech company’s website. Both current investors and those interested in investing in psychedelics will be happy to learn they can access the entirety of the webcast through an archived replay available for an entire month following the conference.
MindMed News of Note
MindMed, a publicly traded company in the United States, Canada and Germany, has developed a much-deserved reputation as a leader in clinical-stage psychedelic medicine. The company’s purpose is to discover, perfect and deploy medicines centered on psychedelics and related therapies to help patients struggling with mental illness, addiction and other pathologies. MindMed has made significant progress in priming the metaphorical pump of psychedelic medicine innovation. The company’s drug treatments include variations of psilocybin, DMT, MDMA, LST and more.
Based in New York City, MindMed recently announced it is set to publish breakthrough human data on the interacting effects of psilocybin used in combination with SSRI. The company also recently announced it will launch a study of LSD’s impact on both cognitive measures and sleep. The study will zero in on the use of low-dose LSD to ameliorate challenges tied to sleep and cognition.
The advancements detailed above are only the tip of the iceberg in terms of MindMed’s progression in mental health treatment with alternative medicine. MindMed’s upcoming presentation at the Benzinga Global Small Cap Conference will reveal additional information about the company’s progression in this rapidly advancing industry niche.
